Speaking to reporters on the sidelines of a cabinet session on Wednesday, Mohammad Eslami said the process of negotiations between Iran and the IAEA is making headway.
He noted that technical and expert delegations representing Iran and the IAEA make reciprocal visits and contacts every day, adding that a report on the results of the talks will be publicized in due time.
He also highlighted Iran’s advances in the production of radiopharmaceuticals, saying 67 types of radiopharmaceuticals are administered to over one million cancer patients in 210 hospitals and medical centers across the country.
Iranian experts in the pharmaceutical industry have in recent years made great headways in producing medicines used to cure a broad range of diseases.
In December 2022, scientists at the AEOI’s Nuclear Science and Technologies Research Center developed the Rhenium-188-based radiopharmaceutical for the treatment of neuroendocrine tumors (NETs).
The new drug containing radioactive isotopes, named 188Re-TOC, is recognized as a promising radiopharmaceutical for diagnosing and curing neuroendocrine tumors.
Eslami said in January that Iran has been ranked among the world’s top five states in the production of radiopharmaceuticals, which are exported to nine foreign countries.